Related Experiment Video
Updated: Jul 19, 2026
07:56
A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
[Monoamine oxidase as a target for drug action]
Jakub Drozak1, Marcin Kozłowski
1Zakład Regulacji Metabolizmu, Instytut Biochemii, Wydział Biologii Uniwersytetu Warszawskiego. jdrozak@biol.uw.edu.pl
Postepy Higieny I Medycyny Doswiadczalnej (Online)
|October 25, 2006
Summary
Monoamine oxidase (MAO) is crucial for regulating brain activity and is implicated in neurodegenerative and depressive disorders. MAO inhibitors are being re-evaluated for treating conditions like Parkinson's and Alzheimer's disease.
Area of Science:
- Biochemistry and Pharmacology
- Neuroscience
Context:
- Monoamine oxidase (MAO) is an enzyme in the outer mitochondrial membrane involved in neurotransmitter and hormone metabolism.
- MAO substrates include neurotransmitters (serotonin, dopamine), hormones, and neurotoxins like MPTP, linking MAO to central nervous system regulation.
- MAO plays a role in the pathogenesis of neurodegenerative and depressive disorders.
Purpose:
- To provide an overview of the physiological importance of Monoamine oxidase (MAO).
- To discuss the biochemical and pharmacological potential of MAO inhibitors.
- To consider the therapeutic applications of MAO inhibitors in human disorders.
Summary:
- MAO, an enzyme catalyzing monoamine oxidative deamination, is vital for regulating neurotransmitters and hormones.
- First-generation MAO inhibitors had therapeutic use but significant side effects.
- Recent interest in MAO and its inhibitors offers new therapeutic avenues for Parkinson's, Alzheimer's, and depression, with ongoing research for safer compounds.
Impact:
- MAO inhibitors are gaining renewed attention for treating neurological and psychiatric conditions.
- The search for novel MAO inhibitors with improved safety profiles is a key area of pharmacological research.
- Understanding MAO's role is critical for developing effective treatments for central nervous system disorders.
More Related Videos
Related Concept Videos
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:26Neurochemical Transmission: Sites of Drug Action
Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...